Non-T cell depletion haploidentical hematopoietic stem-cell transplantation for T lymphoblastic lymphoma
10.3760/cma.j.issn.1009-9921.2011.08.005
- VernacularTitle:非T细胞去除单倍体造血干细胞移植治疗T淋巴母细胞性淋巴瘤的初步临床研究
- Author:
Xuefeng HE
;
Depei WU
;
Aining SUN
;
Xiang ZHANG
;
Huiying QIU
;
Yue HAN
;
Xiaowen TANG
;
Chengcheng FU
;
Zhengming JIN
- Publication Type:Journal Article
- Keywords:
Lymphoma,lymphoblastic;
Haploidentical bone marrow transplantation;
Myeloablative therapy;
T-cell depletion
- From:
Journal of Leukemia & Lymphoma
2011;20(8):459-463
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy of non-T cell depletion haploidentical hematopoietic stem-cell transplantation for T lymphoblastic lymphoma (T-LL). Methods 3 T-LL patients achieving complete remission received haploidentical bone marrow stem cell transplantation with granulocyte-colony-stimulating factor (G-CSF) mobilized bone marrow grafts from related donor without T-cell depletion. Two of them received a myeloablative conditioning regimen consisting of high-doses of cyclophosphamide and cytarabine with total body irradiation, whereas the other was preconditioned with busulfan, cyclophosphamide and cytarabine. All patients received strengthened phophylaxis regimen including rabbit anti-thymocyte globulin against acute graft-versus-host disease. Results All patients had rapid hematopoietic engraftment with the median time for neutrophil and platelet recovery being 12 days and 13 days, respectively. They are still alive without relapse at a median follow-up of 24 months (range: 9-75 months). Conclusion Treatment related toxicity can be acceptable in non-T cell depletion haploidenfical hematopoietic stem-cell transplantation for T-LL and the patients may achieve long term survival.
